Forward

Restructure Information


On May 1, 2026, Imbrium Therapeutics and its parent company Purdue Pharma permanently ceased operations. Knoa Pharma, a new and different company, will continue to oversee development of these important assets. Click here to be taken to the Knoa Pharma website.Click here to be taken to the Knoa Pharma website.


Information relating to the Purdue Pharma Bankruptcy can be found here: Kroll Restructuring Administration, or by calling 844.217.0912 (Toll-Free).


With a dedicated team and a robust pipeline of novel therapy candidates, we work to develop important new medicines that can meaningfully improve the lives of patients around the world.

About Us

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapeutics.

Learn More

Pipeline

Our robust and diversified pipeline of investigational therapy candidates has been built to address many serious medical conditions.

Learn More

Collaboration

Imbrium is dedicated to collaborating with commercial and academic partners to advance novel therapies that address unmet patient need. We welcome the opportunity to learn about new drug development programs and technologies in the areas of CNS, oncology chemotherapeutics, and non-opioid pain. Please reach us at partnering@pharma.com .

Contact

Reach Out